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Abstract
Summary This study demonstrates real-world effectiveness of
teriparatide in reducing the risk of hip and other fragility frac-
tures. Fracture incidence significantly decreased as adherence
and persistence increased for any clinical, vertebral,
nonvertebral, and hip fractures among patients who were ob-
served for 2 years after teriparatide initiation.
Introduction Examine the relationship of treatment adherence
and persistence to teriparatide with hip and other fractures.
Methods Truven MarketScan Research Databases, 2004
through 2014, provided teriparatide users ≥18 years old with
continuous coverage 12 months pre- and 24 months post-
teriparatide prescription. Adherence (medication possession ra-
tio, MPR) groups were defined as high (≥0.80), medium
(0.50 ≤ MPR < 0.80), and low (<0.50). Persistence, allowing
for ≤90-day gaps between prescriptions, was defined as 1–6,
7–12, 13–18, and 19–24 months. Fracture incidence was sum-
marized and compared by using ANOVA and logistic regression
models; the effects of adherence were examined with Cox pro-
portional hazard models with time-dependent covariates for
teriparatide exposure.
Results Among 14,284 teriparatide subjects, mean age was
68.4 years, 89.8% were female, and 29.6% had a fracture in
the previous year; these characteristics were similar across
MPR and persistence groups. The effects of adherence and
persistence to teriparatide were statistically significant
(P < .001) for all fracture types except wrist (P ≥ .125). By
logistic regression, high vs low adherence was associated with
reduced risk for any (OR = 0.67; P < .001); vertebral
(OR = 0.64; P < .001); nonvertebral (OR = 0.71; P < .001);
and hip fractures (OR = 0.52; P < .001) and longer (19–
24 months) vs shorter persistence (1–6 months) was associat-
ed with reduced risk for any (OR = 0.63, P < .001); vertebral
(OR = 0.56, P < .001); nonvertebral (OR = 0.69, P < .001);
and hip fractures (OR = 0.48, P < .001). Cox models revealed
a significantly reduced risk between high and low adherence
for any (OR = 0.69, P < .001); vertebral (OR = 0.60, P < .001);
nonvertebral (OR = 0.77, P < .001); and hip fractures
(OR = 0.55, P < .001).
Conclusion Fracture incidence significantly decreased as per-
sistence and adherence to teriparatide increased.
Keywords Fracture risk reduction . Hip fracture .
Nonvertebral fracture . Real-world effectiveness . Teriparatide
Introduction
In the USA, osteoporosis is an important health concern in the
population of approximately 54million people over the age of 50
[1] and is characterized by reduced bonemineral density (BMD),
deterioration in bone microstructure, and increased risk of frac-
ture [2]. Osteoporosis is the primary underlying cause of fractures
in the elderly and contributes more than 2 million fractures each
year [3]. Fracture incidence increases with age for hip, vertebral,
and most nonvertebral sites [4]. Total incident hip fractures are
expected to increase with the aging of the population, even
though recent studies suggest that hip fracture incidences show
secular declines in the USA [5], Canada [6], and Europe [7, 8] or
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may be leveling off [9]. In the USA from 2015 to 2025, the total
annual number of incident fractures is predicted to rise by 21%
(from 2.51 to 3.04 million), and total hip fractures are projected
to increase by 26% (from 335,000 to 447,000), assuming con-
stant incidence, or to increase by 16%, assuming declining inci-
dence [3].
Hip fractures are associated with increased risk of further
fractures, increased morbidity and mortality, and profound
temporary or permanent impairment of independence and
quality of life [10–14].
Teriparatide (parathyroid hormone [1–34] [recombinant
DNA origin]) stimulates new bone formation on trabecular
and cortical bone surfaces by preferential stimulation of oste-
oblastic activity over osteoclastic activity. In humans, the an-
abolic effects of teriparatide are manifest as an increase in
skeletal mass, an increase in markers of bone formation and
resorption, and an increase in bone strength [15–17].
Teriparatide is approved for treating postmenopausal women
with osteoporosis at high risk for fracture, for increasing bone
mass in men with primary or hypogonadal osteoporosis at
high risk for fracture, and for treating men and women with
glucocorticoid-induced osteoporosis at high risk for fracture
[18, 19]. Teriparatide has been shown to reduce the risk of
vertebral and nonvertebral fractures in randomized clinical
trials [15, 20], in real-world observational studies [21, 22],
and in retrospective claims database studies [23]. However,
real-world evidence is lacking on the effectiveness of
teriparatide in reducing risk of hip fractures.
Proper adherence to medications is essential for achieving
good outcomes [24]. Similar to adherence for other chronic
therapies, adherence to osteoporosis treatments is suboptimal:
more than half of patients failed to comply or persist with their
medication regimens at 1 year [24–29]. Teriparatide therapy
persistence at 12months has been reported to range from 57 to
77% [21, 23, 30, 31].
Previous research on teriparatide adherence and persistence
supports the hypothesis that longer duration and higher rates
of adherence are associated with improved patient outcomes
[20–23, 32–35]. Moreover, retrospective claims database
studies have reported lower nonvertebral fracture incidence
with longer exposures [23, 33, 34]. In the 2012 claims data-
base study by Yu and colleagues, all-clinical, clinical verte-
bral, and nonvertebral fracture incidence were statistically sig-
nificantly lower for more persistent and adherent patients than
for those patients with the least persistence and worst adher-
ence [23]. Because most studies of teriparatide have a relative-
ly small number of fractures, additional information from a
larger group of patients treated with teriparatidemight be help-
ful to clarify the effects of teriparatide on fractures.
Furthermore, previous studies have only examined the asso-
ciation between teriparatide exposure and fracture incidence
and have not adequately evaluated the real-world effective-
ness or possible causality of teriparatide in terms of reducing
the risk of incident fractures. Therefore, our study extends Yu
and colleagues’ 2012 claims database study by using 11 years
of on-market and more recent data to examine both the asso-
ciation and the real-world effectiveness of teriparatide treat-




This study was conducted by using the Truven MarketScan
Research Databases from 01 January 2004 to 31 December
2014.
Study population
The study population consisted of new teriparatide (para-
thyroid hormone [1–34] [recombinant DNA origin]) users
aged 18 years and older. New users were defined as hav-
ing no pharmacy claims for teriparatide during the
12 months before the first prescription dispensed and at
least 1 prescription filled for teriparatide. The date the
first prescription was dispensed was defined as the index
date, with the index teriparatide prescription occurring
between 1 January 2005 and 31 December 2012. New
users were required to have continuous medical and phar-
macy coverage 12 months before and 24 months after the
first teriparatide prescription was dispensed. Patients di-
agnosed with Paget disease were ident i f ied by
International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) code 731.0 and/or spe-
cific medication dosing (alendronate sodium 40 mg daily
and risedronate sodium 30 mg daily) and were excluded
from the study population.
Baseline patient characteristics, including age and gender,
were recorded as of the date of the first teriparatide prescrip-
tion. Clinical characteristics included assessments of health
status, measured by the Deyo Charlson Comorbidity Index
(CCI), whether a BMD test had been performed, and the num-
ber of fractures reported during the 12 months before the first
teriparatide prescription. Confounding medications included
osteoporosis medications (bisphosphonates, selective estro-
gen receptor modulator [SERM], calcitonin, denosumab, and
hormone therapy) and medications known to be associated
with bone loss or risk of fracture (glucocorticoids, hormone
deprivation therapy, anticonvulsants, and immunosuppres-
sants) [26, 36, 37]. All baseline characteristics were used as
covariates in the multivariate regression models. All covari-
ates were categorical variables except age and Deyo CCI
score, which were continuous variables.
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Adherence and persistence
Medication adherence was measured by the medication pos-
session ratio (MPR), defined as the sum of days of supply
dispensed divided by the total number of days of the post-
index period. An MPR greater than or equal to 0.80 was de-
fined as high, 0.50 ≤MPR < 0.80 was defined as medium, and
<0.50 was defined as low adherence for osteoporosis medica-
tion [23–25].
Medication persistence was measured as teriparatide use
with gaps in treatment of less than or equal to 90 days, where
the gap was measured from last date of therapy (date of last
day of drug supply) to the beginning date of the subsequent
therapy prescription. All patients without gaps in teriparatide
of more than 90 days were considered Bpersistent.^
Medication persistence was calculated as a categorical vari-
able, and patients were entered into 1 of 4 persistence groups:
1–6, 7–12, 13–18, and 19–24 months. Medication persistence
categorical variables were used in the descriptive and multi-
variate regression analyses.
Fractures
New incident fractures were identified by a claims-based al-
gorithm at the 3-digit level of an ICD-9-CM code (see Online
Resource 1). Fracture sites were categorized as any, vertebral,
nonvertebral, hip, and wrist. Pathological fractures were in-
cluded on the basis of the recommendation by Curtis and
colleagues from epidemiologic studies of osteoporotic frac-
tures [38]. Fractures that occurred after 90 days from the index
date were considered incident fractures to provide sufficient
time for therapeutic effects from teriparatide to begin. The 90-
day interval for onset of teriparatide effect is supported by
work from Bonafede et al. using the same claims database
[34]; during the year prior to teriparatide, 25.6% of the patients
had fragility fracture claims and this approximate rate of frac-
ture continued during the initial 90 days of teriparatide, but
was lower thereafter [34, 35]. Hip fractures were identified by
fracture diagnoses from inpatient admission claims. Vertebral
fractures were identified by spine imaging tests within 30 days
of fracture diagnoses. Nonvertebral and other fractures were
identified from the primary ICD-9-CM codes on inpatient or
outpatient admission claims. Subsequent fracture diagnoses
could be claimed if the new claim was >180 days from the
original fracture.
Statistical methods
SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was
used for analytic file construction and all statistical analyses.
Descriptive statistics for baseline and clinical characteristics,
medication use, and previous fracture history were reported
for the total study population and by MPR and persistence
groups. Mean and standard deviation were reported for con-
tinuous variables, and number and percentage were reported
for categorical variables. Means were tested using analysis of
variance (ANOVA); percentages were tested using chi-square
tests.
Unadjusted fracture incidence per 1000 patient years (PYs)
were reported by fracture type and compared using ANOVA.
The association between teriparatide exposure, based on per-
sistence and adherence categories, and incident fractures was
evaluated by using logistic regression analyses performed by
fracture type (any, vertebral, nonvertebral, hip, and wrist) for
modeling the probability of fractures over 24months, adjusted
forMPR and persistence in a time-invariant manner, and base-
line covariates. Odds ratios (OR), 95% confidence intervals,
and associated P values were reported for all the variables
included in the logistic regressions, as were the type III anal-
yses of effects for categorical variables with more than two
categories.
Real-world effectiveness of adherence to teriparatide ther-
apy on particular fracture site risk, by fracture type (any, ver-
tebral, nonvertebral, hip, and wrist), was analyzed with Cox
proportional hazard models using time-dependent cumulative
adherence of teriparatide (censored at time of first outcome
fracture or 24 months), adjusting for occurrence of other frac-
tures (yes/no) preceding the main fracture outcome and
adjusting for all baseline covariates used in logistic regression
models above. The dependent variable in each model was
time to the first incident fracture, and patients’ adherence
levels (low, moderate, or high) were calculated from the index
date in cumulative 30-day intervals.When a fracture occurred,
the cumulative MPR for the period preceding the fracture was
applied.
In real-world settings, a source of possible confounding is
the Bhealthy adherer^ effect or Badherence bias,^ whereby
patients who are more adherent to medications may differ in
important health-seeking behaviors and other aspects that af-
fect outcomes from those who are not adherent to their med-
ications. This phenomenon may lead to biased estimates of
treatment effects when health status and healthy behaviors
are not measured and adjusted for in the analyses. Claims
databases (including the Truven MarketScan Research
Databases used in this study) have limited or insufficient mea-
sures of health status and healthly lifestyle behaviors.
Therefore, we conducted diagnostic tests for potential healthy
adherer bias using control outcomes hypothesized to be unre-
lated to osteoporosis or teriparatide’s treatment effects [39,
40]. As proxy measures, differences in these outcomes be-
tween adherence groups would reflect underlying, unmeasured
differerences in health status and/or healthy behaviors. The
control outcomes or Bfalsification^ endpoints used to test for
differences by teriparatide persistence and adherence groups
included the six most frequent hospital admissions (expected
to be unrelated to osteoporosis or teriparatide’s effects)
Osteoporos Int (2017) 28:799–809 801
during the post-index period (i.e., those with primary ICD-9-
CM diagnoses of 486 [pneumonia, organism unspecified];
491.21 [obstructive chronic bronchitis, with [acute] exacerba-
tion]; 599.0 [urinary tract infection, site not specified]; 427.31
[atrial fibrillation]; 414.01 [coronary atherosclerosis of native
coronary artery]; or 038.9 [unspecified septicemia]) (see
Online Resource 2, 3, 4).
Results
There were 14,284 new teriparatide users aged 18 years or
older reported in this study (Fig. 1). The numbers of patients
in the low-, medium-, and high-MPR groups were 5469
(38.3%), 2442 (17.1%), and 6373 (44.6%), respectively
(Table 1). The numbers of patients in the 1–6, 7–12, 13–18,
and 19–24 months persistence groups were 3916 (27.4%),
1968 (13.8%), 1842 (12.9%), and 6558 (45.9%), respectively
(Table 2). Baseline characteristics included mean age
68.35 years, 89.8% female, and 29.6% had a previous fracture
(Table 1). The baseline Deyo CCI score was significantly
different across MPR groups, with scores higher (representing
worse health scores) in the low-MPR group (1.09) than in the
high-MPR group (0.90). The frequency of patients who had a
BMD test prior to beginning teriparatide was significantly
greater in the high-MPR group (85.0%) than in the low-
MPR group (77.7%). Baseline glucocorticoid and anticonvul-
sant use was significantly more common in the low-MPR
group (44.2 and 18.8%, respectively) than in the high-MPR
group (37.9 and 15.1%), and baseline bisphosphonate and
SERM use was more common in the high-MPR group (59.3
and 11.0%, respectively) than in the low-MPR group (43.2
and 8.4%, respectively) (all P < .001; Table 1). Similar base-
line results were observed across persistence groups; Deyo
CCI scores were highest in the 1–6-month persistence group
(1.15), BMD test frequency was highest in the 19–24-month
persistence group (85.0%), glucocorticoid and anticonvulsant
use was most common in the 1–6-month persistence group
(45.3 and 19.5%, respectively), and bisphosphonate and
SERM use was most common in the 19–24-month persistence
group (58.9 and 11.0%, respectively) (all P < .001; Table 2).
The mean (SD) exposure to teriparatide was 431.7
(260.2) days. The unadjusted incidence per 1000 PYs by
MPR group for any clinical fracture ranged from 82.9 (low
MPR) to 55.6 (high MPR). Fracture incidence per 1000 PYs
by MPR group is displayed graphically in Fig. 2a. The unad-
justed incidence per 1000 PYs by persistence group for any
clinical fracture ranged from 91.2 (1–6 months) to 55.5 (19–
24 months). Fracture incidence per 1000 PYs by persistence
group is displayed graphically in Fig. 2b. The proportion of
patients with one fracture or with multiple fractures generally
decreased as MPR or persistence increased for all fracture
types except wrist fracture (see Online Resource 5).
The results from the logistic regressionmodels indicate that
the effects of adherence and persistence were statistically sig-
nificant (P < .001) for all fracture types except wrist fracture
(P ≥ .125) (Table 3). Furthermore, high adherence (MPR) was
associated with significantly lower risk than low adherence for
any fracture (O = 0.67; P < .001), vertebral fracture
(OR = 0.64; P < .001), nonvertebral fracture (OR = 0.71;
P < .001), and hip fracture (OR = 0.52; P < .001). High and
medium adherence compared to low adherence was not asso-
ciated with reduced risk for wrist fracture (Table 3). Patients
with longer persistence (19–24 months) were significantly
less likely than patients with shorter persistence (1–6 months)
to have any fracture (OR = 0.63, P < .001), vertebral fracture
(OR = 0.56, P < .001), nonvertebral fracture (OR = 0.69,
P < .001), and hip fracture (OR = 0.48, P < .001, Table 3).
In Cox proportional hazard modeling (Table 4), the effect
of adherence to teriparatide was statistically significant
(P ≤ .002) for all fracture types except wrist fracture
(P = .55). In addition, significantly lower risk was seen for
any fracture (OR = 0.79, P = .001) and vertebral fracture
(OR = 0.68, P < .001) for medium adherence than for low
adherence and for any fracture (OR = 0.69, P < .001), verte-
bral fracture (OR = 0.60, P < .001), nonvertebral fracture
(OR = 0.77, P < .001), and hip fracture (OR = 0.55,
P < .001) for high adherence than for low adherence (see
Online Resource 6 for a complete presentation of all factors
in the model; these results were similar to those seen with the
logistic regression).
After stopping teriparatide (a treatment gap of at least
90 days), use of osteoporosis medications other than
teriparatide was 45.1% (31.8% bisphosphonate) in the 1 to
6-month group, 36.9% (23.8% bisphosphonate) in the 7 to
12-month group, 32.6% (20.5% bisphosphonate) in the 13 to
18-month group, and 14.6% (8.1% bisphosphonate) in the
19–24-month group. The control outcomes analyses revealed
inconsistent evidence regarding potential healthy adherer bias.
In two of the six hospital admission types, there were statisti-
cally significant differences in the incidence per 1000 PYs
across the adherence and persistence groups (urinary tract in-
fection), while coronary athlerosclerosis of native coronary
Fig. 1 Patient selection
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artery had a statistically significant difference across persis-
tence groups but not for adherence groups. However, even
where statistically significant differences were found, the in-
cidence patterns generally were not consistent across the ex-
posure groups, as increases and decreases in incidence were
observed with longer persistence. There were no statistically
significant differences estimated in any of the analyses for
pneumonia–organism unspecified, obstructive chronic bron-
chitis with acute exacerbation, atrial fibrillation, or unspeci-
fied septicemia (see Online Resource 2, 3, 4).
Discussion
Evidence of therapy benefits under real-world clinical condi-
tions, or real-world evidence, is becoming increasingly impor-
tant to payers and health care providers as the need to allocate
scarce budgets more efficiently and to improve patient out-
comes intensifies. The current study uses a real-world US
claims database to examine the relationship between
teriparatide adherence and persistence and hip and other frac-
ture incidences. The results show fracture incidence decreased
as adherence or persistence increased for any, vertebral,
nonvertebral, and hip fractures.
Hip fracture is an important clinical end point for osteopo-
rosis medications. In many smaller studies, the hip fracture
end point has not been examined because of insufficient num-
bers of events. A recent review of teriparatide use reported
increases in cancellous bone volume, improvement in bone
architecture, and increases in cortical thickness associated
with increased cortical remodeling [41]. Additionally,
teriparatide 20 μg/day increased femoral neck and total hip
BMD; the gains continued during ongoing treatment through
24 months [41]. The Direct Assessment of Nonvertebral
Fractures in Community Experience (DANCE) study evalu-
ated over 4000 men and women receiving teriparatide for
24 months who were then followed up for an additional
24 months after treatment [41, 22]. The incidence of patients
experiencing a new nonvertebral fragility fracture was 1.42,
0.91, 0.70, and 0.81% for the 0–6-, 6–12-, 12–18-, and 18–24-
month treatment periods, and this trend persisted after
teriparatide treatment was discontinued [22, 41]. Hip fractures
as a percentage of patients at risk decreased as treatment du-
ration increased 0.27% (10/3720 patients), 0.067% (2/3010
patients), 0.15% (4/2629 patients), and 0% (0/2287 patients)
for the 0–6-, 6–12-, 12–18-, and 18–24-month treatment pe-
riods [41].
Table 1 Baseline characteristics by MPR group
MPR
Total (N = 14,284) Low (N = 5469) Medium (N = 2442) High (N = 6373) P value
Age, years
Age, mean (SD) 68.35 (12.01) 68.06 (12.91) 67.56 (12.00) 68.90 (11.15) <.001
Age group, N (%) <.001
18–44 284 (2.0) 171 (3.1) 52 (2.1) 61 (1.0)
45–54 1445 (10.1) 650 (11.9) 263 (10.8) 532 (8.3)
55–64 4220 (29.5) 1506 (27.5) 794 (32.5) 1920 (30.1)
65–74 3299 (23.1) 1146 (21.0) 550 (22.5) 1603 (25.2)
75–84 3845 (26.9) 1473 (26.9) 590 (24.2) 1782 (28.0)
≥ 85 1191 (8.3) 523 (9.6) 193 (7.9) 475 (7.5)
Sex, N (%)
Female 12,822 (89.8) 4904 (89.7) 2207 (90.4) 5711 (89.6) .55
Male 1462 (10.2) 565 (10.3) 235 (9.6) 662 (10.4)
Clinical characteristics
BMD test (yes/no), N (%) 11,722 (82.1) 4249 (77.7) 2058 (84.3) 5415 (85.0) <.001
Previous fracture (yes/no), N (%) 4235 (29.6) 1593 (29.1) 767 (31.4) 1875 (29.4) .11
Deyo CCI, mean (SD) 0.99 (1.42) 1.09 (1.49) 1.02 (1.44) 0.90 (1.35) <.001
Confounding medication, N (%)
Glucocorticoids 5872 (41.1) 2417 (44.2) 1040 (42.6) 2415 (37.9) <.001
Hormone deprivation 154 (1.1) 58 (1.1) 27 (1.1) 69 (1.1) .98
Anticonvulsants 2450 (17.2) 1029 (18.8) 458 (18.8) 963 (15.1) <.001
Immunosuppressants 1367 (9.6) 526 (9.6) 260 (10.6) 581 (9.1) .09
Other OP medication, N (%)
Bisphosphonates 7392 (51.8) 2360 (43.2) 1255 (51.4) 3777 (59.3) <.001
SERM use 1393 (9.8) 457 (8.4) 238 (9.7) 698 (11.0) <.001
Calcitonin 9 (0.1) 4 (0.1) 3 (0.1) 2 (0.0) .29
Denosumab 5 (0.0) 2 (0.0) 1 (0.0) 2 (0.0) .97
Hormone therapy 1794 (12.6) 687 (12.6) 317 (13.0) 790 (12.4) .75
P values for frequencies obtained from chi-square tests; P values for mean age and mean Deyo CCI scores obtained from ANOVA F test
ANOVA analysis of variance, BMD bone mineral density, CCI Charlson comorbidity index, MPR medication possession ratio, OP osteoporosis, SD
standard deviation, SERM selective estrogen receptor modulator
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In Yu and colleagues’ study, hip fracture incidence
appeared to decrease with longer exposure, though in
multivariate models the association of teriparatide expo-
sure and incidence did not reach statistical significance
(persistence 1–6 vs 19–24 months: OR = 1.93;
P = .08). Our study extends the work of Yu and col-
leagues by using a larger and more recent database and
by applying Cox proportional hazard models with time-
dependent covariates for cumulative teriparatide expo-
sure to show the effect of adherence to therapy on frac-
ture incidence. Our study is the first to demonstrate
real-world effectiveness of teriparatide in reducing the
risk of hip and other fragility fractures in the USA.
The wrist has proven to be a difficult site for which
to demonstrate reduced fracture risk in studies of oste-
oporosis because high forces are applied to the wrist as
people brace themselves with their hands when falling,
so it is common for people with healthy bones to expe-
rience wrist fractures. Clinical trials of osteoporosis
drugs have shown inconsistent effects on wrist fractures
or not reported this outcome [42]. Our study reveals an
inconsistent reduction in wrist fractures by MPR and
persistence categories using logistic and Cox regres-
sions; statistical significance was not achieved. The fact
that increased teriparatide adherence and persistence did
not significantly reduce wrist fracture risk might relate
to teriparatide increasing cortical remodeling [41] and
decreasing bone mineral density at the radius [15], al-
though teriparatide increases cortical thickness [41].
Alternatively, the lack of significance might be due to
an insufficient number of wrist fractures; future analyses
with larger numbers of events may clarify the effect of
teriparatide at this site.
The study’s limitations include those typical when
claims databases are used, including lack of randomiza-
tion, potential miscoding of the fracture type or
overestimating or underestimating the fracture inci-
dences; use of algorithms whose validity and reliability
have not been established to identify incident fractures;
lack of information on clinical risk factors (e.g., limited
medical history, no family medical history, lifestyle risk
factors, no BMD T scores); and the inability to ascertain
actual patient adherence (e.g., proper injections) to ther-
apy. In observational studies examining osteoporosis














Age, mean (SD) 68.35 (12.01) 67.46 (13.08) 67.08 (12.28) 67.67 (11.94) 68.86 (11.21) <.001
Age group, N (%) <.001
18–44 284 (2.0) 133 (3.4) 44 (2.2) 39 (2.1) 68 (1.0)
45–54 1445 (10.1) 440 (11.2) 267 (13.6) 189 (10.3) 549 (8.4)
55–64 4220 (29.5) 1029 (26.3) 606 (30.8) 599 (32.5) 1986 (30.3)
65–74 3299 (23.1) 821 (21.0) 424 (21.5) 414 (22.5) 1640 (25.0)
75–84 3845 (26.9) 1084 (27.7) 485 (24.6) 457 (24.8) 1819 (27.7)
≥ 85 1191 (8.3) 409 (10.4) 142 (7.2) 144 (7.8) 496 (7.6)
Sex, N (%)
Female 12,822 (89.8) 3501 (89.4) 1780 (90.4) 1662 (90.2) 5879 (89.6) .55
Male 1462 (10.2) 415 (10.6) 188 (9.6) 180 (9.8) 679 (10.4)
Clinical characteristics
BMD test (yes/no), N (%) 11,722 (82.1) 3003 (76.7) 1586 (80.6) 1559 (84.6) 5574 (85.0) <.001
Previous fracture (yes/no), N (%) 4235 (29.6) 1162 (29.7) 562 (28.6) 575 (31.2) 1936 (29.5) .34
Deyo CCI, mean (SD) 0.99 (1.42) 1.15 (1.50) 0.99 (1.47) 1.00 (1.41) 0.90 (1.35) <.001
Confounding medication, N (%)
Glucocorticoids 5872 (41.1) 1773 (45.3) 841 (42.7) 745 (40.4) 2513 (38.3) <.001
Hormone deprivation 154 (1.1) 45 (1.1) 17 (0.9) 22 (1.2) 70 (1.1) .74
Anticonvulsants 2450 (17.2) 763 (19.5) 362 (18.4) 337 (18.3) 988 (15.1) <.001
Immunosuppressants 1367 (9.6) 388 (9.9) 202 (10.3) 179 (9.7) 598 (9.1) .36
Other OP medication, N (%)
Bisphosphonates 7392 (51.8) 1668 (42.6) 901 (45.8) 958 (52.0) 3865 (58.9) <.001
SERM 1393 (9.8) 312 (8.0) 188 (9.6) 173 (9.4) 720 (11.0) <.001
Calcitonin 9 (0.1) 3 (0.1) 1 (0.1) 2 (0.1) 3 (0.0) .78
Denosumab 5 (0.0) 2 (0.1) 0 1 (0.1) 2 (0.0) .75
Hormone therapy 1794 (12.6) 488 (12.5) 263 (13.4) 241 (13.1) 802 (12.2) .51
P values for frequencies obtained from chi-square tests; P values for mean age and mean Deyo CCI scores obtained from ANOVA F test
ANOVA analysis of variance, BMD bone mineral density, CCI Charlson Comorbidity Index, OP osteoporosis, SD standard deviation, SERM selective
estrogen receptor modulator
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therapy adherence and healthy adherer bias, only limited
evidence was found [39, 43]. In one study on Medicare
patients, the association between high adherence with
different medications (oral bisphosphonates, selective
serotonine re-uptake inhibitors, angiotensin converting
enzyme inhibitors, and calcium channel blockers) and
fracture was examined to test for possible healthy
adherer bias; and the authors concluded that the healthy
adherer effect was limited [39]. Another study examined
the potential for healthy adherer bias in elderly
Medicaid patients in Pennsylvania by estimating the as-
sociation between adherence to osteoporosis therapies
(raloxifene, calcitonin, oral bisphosphonates) and subse-
quent vaccination and health care testing [43]. The au-
thors reported there was limited evidence of a healthy
adherer effect, although higher adherence with raloxi-
fene was associated with higher fracture risk and was
probably due to residual confounding in those patients
[43]. In our study, we examined six separate control
outcomes and found mixed results and thus did not
detect any strong evidence of healthy adherer bias.
Nevertheless, we cannot conclusively claim absence of
healthy adherer effects or bias within our estimates,
though any such impacts would appear to be minimal.
The use of osteoporosis medications known to reduce
fracture risk after stopping teriparatide may represent a
bias against showing teriparatide effectiveness in this
analysis. Additionally, claims for incident fractures, es-
pecially with respect to incident compression vertebral
fractures may be incorrect, and misclassification of out-
comes may also represent a bias reducing the associa-
tion of adherence with fracture risk reduction [44].
In summary, teriparatide stimulates bone formation at the
femur by histology, bone scan, and PET scan and has proven
to increase femoral neck and total hip BMD [41, 45]. Clinical,
observational, and claims database studies show fewer
nonvertebral fractures (a composite end point including hip
fractures) with longer teriparatide treatment than with shorter
teriparatide treatment. The DANCE study and Yu and col-
leagues’ claims database study show apparent decreases in
numbers of hip fractures with longer than with shorter
teriparatide treatment, although statistical significance was
not reached in the Yu and colleagues study. Our study, with
a larger sample of teriparatide-treated patients, confirms a
A
Analysis of variance (ANOVA) F-tests across medication possession ratio (MPR) groups showed significant differences for all fracture 
categories (p<.0001) except wrist (p=.169).
An MPR greater than or equal to 0.80 was defined as high, 0.50    MPR <0.80 was defined as medium, and <0.50 was defined as low  
adherence for osteoporosis medication
B
Analysis of variance (ANOVA) F-tests across persistence groups showed signiﬁcant diﬀerences for all fracture categories (p<.0001) except
wrist (p=.424).
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Fig. 2 Fracture incidence per 1000 patient years
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statistically significant reduction in hip and other fragility frac-
tures with longer persistence or higher adherence.
Conclusion
This study is the first to demonstrate real-world effectiveness
of teriparatide to reduce the risk of hip fractures along with
other fragility fractures in the USA. Among teriparatide pa-
tients in a US claims database who were observed for 2 years
after teriparatide initiation, fracture incidence significantly de-
creased as adherence and persistence increased for vertebral,
nonvertebral, hip, and any clinical fractures.
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